FDA declines to approve Daiichi Sankyo's blood cancer treatment
Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.
from Reuters: Health News https://reut.rs/2N4vruM
http://bit.ly/2zwRqiM